Companies /Healthcare

PepGen Inc

NASDAQ: PEPG Biotechnology
$2.72
▼ $0.15 (−5.23%) today
Markets closed · 5:12pm ET

PEPG at a Glance

Valuation
Market cap
$181.2M
Profitability
EPS (TTM)
$-1.01
Price
52-week range
$1 – $8
Street target
$10.19
Earnings
Next report
Nov 11, 2026

Headquartered in Boston, MA Fiscal year ends December NASDAQ: PEPG pepgen.com

About PepGen

PepGen Inc. is a clinical-stage biotechnology company developing next-generation oligonucleotide therapies for severe neuromuscular and neurological diseases. The company's proprietary Enhanced Delivery Oligonucleotide (EDO) platform leverages cell-penetrating peptides to improve the uptake and nuclear delivery of conjugated oligonucleotide therapeutics, addressing a key limitation of prior approaches. PepGen's lead candidate, PGN-EDODM1, is being developed for myotonic dystrophy type 1 (DM1), a genetic disease affecting more than 110,000 patients in the U.S. and EU with no approved disease-modifying therapies. PGN-EDODM1 has received Orphan Drug and Fast Track Designations from the FDA and Orphan Designation from the EMA. The company is also exploring its EDO platform in other genetic conditions, including Charcot-Marie-Tooth disease. PepGen is pre-revenue with no approved products and trades on Nasdaq under the ticker PEPG. Updated

PEPG Coverage

Frequently Asked Questions

What does PepGen do?

PepGen Inc. is a clinical-stage biotechnology company developing next-generation oligonucleotide therapies for severe neuromuscular and neurological diseases.

What is the PEPG stock price target?

The Wall Street consensus 12-month price target for PEPG is $10.19.